Cytel Acquires Laiya Consulting
Cytel Inc. has announced the acquisition of Laiya Consulting, a drug development solutions company specializing in Bayesian adaptive trial designs and implementation. The deal follows the recent release of Cytel’s East Alloy platform for easy access to verified Bayesian tools, and marks the latest step in Cytel’s commitment aiming to broadenin industry access to clinical trial design methods.
"As we look to make the benefits of sophisticated Bayesian methods ever more accessible to drug developers, we’re taking strategic leaps to both bolster our core offerings and streamline their delivery to the market," said Yannis Jemiai, Chief Scientific Officer at Cytel. "Partnering with Laiya allows us to smoothly feed into our broad Bayesian software capabilities with ever greater levels of statistical innovation and expertise. We look forward to welcoming Dr Yuan Ji and his colleagues to the team."
"Bayesian approaches, when applied correctly, open an abundance of opportunity in clinical development, evidenced by our own and Cytel’s extensive work in this field," said Dr Yuan Ji, Co-founder of Laiya Consulting. "Merging with Cytel means unifying two rich sources of statistical proficiency to continue setting new standards for Bayesian design, which will ultimately help us to further enable drug developers to profitably solve the most intricate clinical challenges."
Read the full release, here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
